Plain-language overview
Tirzepatide is a dual GIP/GLP-1 receptor agonist. The same molecule is FDA-approved under the brand names Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). YourHealthRx partner workflows discuss an oral dissolving (ODT) option and an injectable option combined with cyanocobalamin (vitamin B12).
Mechanism & background
Tirzepatide activates both the GIP and GLP-1 receptors. In the literature, this dual-incretin action is associated with satiety, slower gastric emptying, and improved insulin sensitivity.
Class: Dual GIP / GLP-1 receptor agonist
Where this may fit
Most often discussed for chronic weight-management and metabolic-health goals. Suitability for any individual is determined by the reviewing clinician.
Safety screening & clinician review
Every option below begins with a screening-led intake and review by a licensed clinician through our partner workflow. The incretin class shares a side-effect and contraindication profile with semaglutide (GI effects during titration; medullary thyroid carcinoma / MEN-2 contraindications; a pancreatitis consideration). Compounded availability is jurisdiction-dependent. YourHealthRx does not diagnose, prescribe, or determine dosing.